FDA declines to grant EUA for antidepressant to treat Covid-19
The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.
Therapy Areas
Latest in
Therapy Areas
EC to terminate Covid-19 vaccine deal with Valneva
The EC can terminate the agreement if the vaccine does not obtain marketing authorisation from EMA by the end of…
Pfizer and BioNTech amend Covid-19 vaccine supply deal with EC
The vaccine doses planned to be supplied between June and August will now be delivered from September to Q4 of…
FDA grants Orphan Drug Designation to Editas’ beta thalassemia therapy
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.
Takeda announces 11.6% reported revenue growth in FY2021
For the fiscal year, the operating cash flow witnessed a 11.1% rise to $8.63bn (JPY1,123.1bn).
Sound Pharmaceuticals receives NIH grant for Covid-19 therapy development
The grant will support two trials of ebselen in 120 adult subjects with moderate or severe Covid-19.
FDA grants approval for Lilly-Incyte’s Covid-19 treatment
The approval is based on findings from two Phase III clinical trials, ACTT-2 and COV-BARRIER.
API and University of Waterloo to develop coronavirus drugs
This alliance is the third academic-industry partnership of API this year to develop therapies against viral variants.